US 12,109,310 B2
Exosome extracellular vesicles and methods of use
Hadi Valadi, Gothenburg (SE); and Lennart Lindfors, Mölndal (SE)
Assigned to Hadi Valadi, Gothenburg (SE); and Astraeneca AB, Sodertalje (SE)
Appl. No. 16/972,190
Filed by AstraZeneca AB; and Hadi Valadi, Gothenburg (SE)
PCT Filed Jun. 27, 2019, PCT No. PCT/EP2019/067232
§ 371(c)(1), (2) Date Dec. 4, 2020,
PCT Pub. No. WO2020/002540, PCT Pub. Date Jan. 2, 2020.
Claims priority of provisional application 62/691,348, filed on Jun. 28, 2018.
Prior Publication US 2021/0315819 A1, Oct. 14, 2021
Int. Cl. A61K 9/127 (2006.01); A61K 31/7115 (2006.01)
CPC A61K 9/1272 (2013.01) [A61K 31/7115 (2013.01)] 16 Claims
OG exemplary drawing
 
1. An isolated exosome comprising a modified ribonucleic acid (RNA) prepared by a process comprising:
(a) providing one or more lipid nanoparticles (LNP) comprising the modified RNA;
(b) contacting one or more cells with the LNP under conditions that allow LNP uptake by the one or more cells; and
(c) isolating exosomes produced by the one or more cells, wherein at least one isolated exosome comprises the modified RNA;
wherein the exosome comprises an ionizable lipid:modified RNA nucleotides molar ratio of about 1:1 to about 3:1, or less than about 1:1.